Poland· PL-100310938
Incresync
A pioglitazone and alogliptin product containing alogliptinum + pioglitazonum, registered in Poland by Takeda Pharma A/S. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Pioglitazone and alogliptin is registered in 9 of 19 countries.
Countries holding a registration under ATC A10BD09 (pioglitazone and alogliptin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Pioglitazone and alogliptin · ATC A10BD09
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Alogliptinum + Pioglitazonum
- Manufacturer
- Takeda Pharma A/S
- Country
- Poland (PL)
- ATC code
- A10BD09
- ATC class
- Pioglitazone and alogliptin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pioglitazone and alogliptin in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenIncresync 12,5 mg/30 mg Filmdragerad tablettTakeda Pharma A/S
- IcelandIncresyncTakeda Pharma A/S*
- NetherlandsIncresync 12,5 mg/30 mg filmomhulde tabletTakeda Pharma A/S
- SpainIncresync 12,5 mg/30 mg comprimidos recubiertos con peliculaTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Incresync
- Liechtenstein · Incresync
- Norway · Incresync
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8eba13f8-2a4d-491f-b00c-9f261f9deeec GET /v1/drugs/8eba13f8-2a4d-491f-b00c-9f261f9deeec?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "25 mg + 45 mg",
"packaging": "Rp ¦ EU/1/13/842/028 ¦ 89353\n10 tabl.\nRp ¦ EU/1/13/842/029 ¦ 89354\n14 tabl.\nRp ¦ EU/1/13/842/030 ¦ 89355\n28 tabl.\nRp ¦ EU/1/13/842/031 ¦ 89356\n30 tabl.\nRp ¦ EU/1/13/842/032 ¦ 89357\n56 tabl.\nRp ¦ EU/1/13/842/033 ¦ 89358\n60 tabl.\nRp ¦ EU/1/13/842/034 ¦ 89359\n90 tabl.\nRp ¦ EU/1/13/842/035 ¦ 89360\n98 tabl.\nRp ¦ EU/1/13/842/036 ¦ 89361\n100 tabl.",
"substance": "Alogliptinum 25 mg + Pioglitazonum 45 mg",
"common_name": "Alogliptinum + Pioglitazonum",
"pl_product_id": "100310938",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about pioglitazone and alogliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.